Keytruda® was first approved by the FDA in 2014 for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Here, BRAF is linked to metastatic melanoma.